Jubilant Ingrevia Limited (NSE:JUBLINGREA)
India
· Delayed Price · Currency is INR | Market Cap | 113.90B |
| Revenue (ttm) | 42.61B |
| Net Income (ttm) | 2.66B |
| Shares Out | 158.13M |
| EPS (ttm) | 16.76 |
| PE Ratio | 42.98 |
| Forward PE | 32.85 |
| Dividend | 5.00 (0.68%) |
| Ex-Dividend Date | Feb 10, 2026 |
| Volume | 135,556 |
| Average Volume | 409,444 |
| Open | 722.00 |
| Previous Close | 720.30 |
| Day's Range | 700.25 - 727.45 |
| 52-Week Range | 537.30 - 851.80 |
| Beta | 0.21 |
| RSI | 63.01 |
| Earnings Date | May 12, 2026 |
About Jubilant Ingrevia
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition... [Read more]
Financial Performance
In fiscal year 2025, Jubilant Ingrevia's revenue was 41.78 billion, an increase of 1.01% compared to the previous year's 41.36 billion. Earnings were 2.51 billion, an increase of 37.34%.
Financial StatementsNews
Jubilant Ingrevia grants 3,43,569 stock options under employee plan
Jubilant Ingrevia has announced the grant of 3,43,569 stock options to eligible employees under its Employees Stock Option Plan 2021. This decision was approved by the Nomination, Remuneration and Com...
Jubilant Ingrevia completes acquisition of 100% stake in Remidex Pharma
Jubilant Ingrevia has successfully acquired a 100% equity stake in Remidex Pharma Private Limited. This acquisition was completed as per the Share Purchase Agreement previously announced by the compan...
Jubilant Ingrevia's subsidiary begins commercial production at Bharuch site
Jubilant Ingrevia Limited has announced that its wholly owned subsidiary, Jubilant Agro Sciences Limited, has commenced commercial production of agro intermediates at its Bharuch site. This developmen...
Jubilant Ingrevia to acquire Remidex Pharma for Rs 16.5 crore
Jubilant Ingrevia has announced its acquisition of Remidex Pharma Private Limited for ₹16.5 crore, marking a strategic expansion into the human nutrition sector. Remidex, based in Bangalore and establ...
Brokerage radar, March 10: Dixon Technologies, Meesho, Jubilant Ingrevia, Amber Enterprises among top stocks to watch today
Brokerage firms released several key stock recommendations and sector outlooks on March 10 (IST), covering companies across electronics manufacturing, insurance, defence, chemicals, and oil marketing....
Jubilant Ingrevia Ltd (BOM:543271) Q3 2026 Earnings Call Highlights: Resilient Performance Amid ...
Jubilant Ingrevia Ltd (BOM:543271) Q3 2026 Earnings Call Highlights: Resilient Performance Amid Market Challenges
Q3 2026 Jubilant Ingrevia Ltd Earnings Call Transcript
Q3 2026 Jubilant Ingrevia Ltd Earnings Call Transcript
Jubilant Ingrevia Transcript: Q3 25/26
Specialty chemicals and nutrition segments drove volume and EBITDA growth despite pricing pressures, with strong CDMO pipeline wins and major capacity expansions underway. FTAs and cost initiatives are expected to support margin recovery and market share gains in coming quarters.
Top stocks to watch today, October 28: Jubilant Ingrevia, PNB Housing, Indus Tower, Sona BLW, JK Tyre and more
Indian stock markets are expected to remain stock-specific on Tuesday, October 28, with several companies in focus following key announcements,...
Jubilant Ingrevia Ltd (BOM:543271) Q2 2026 Earnings Call Highlights: Record Revenue and ...
Jubilant Ingrevia Ltd (BOM:543271) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Plans Amid Pricing Pressures
Q2 2026 Jubilant Ingrevia Ltd Earnings Call Transcript
Q2 2026 Jubilant Ingrevia Ltd Earnings Call Transcript
Jubilant Ingrevia Transcript: Q2 25/26
Q2 and H1 FY26 saw record revenue and volume growth, led by specialty chemicals and robust CDMO pipeline. Margins improved despite pricing pressures, with strong cost controls and new capacity expansions supporting future growth.
Jubilant Ingrevia Q2 Results: Revenue jumps 7.2% YoY to Rs 1,120.7 crore, net profit up 17.8%
Jubilant Ingrevia Limited reported a steady performance in the September quarter of FY26, with both revenue and profit showing year-on-year...
Jubilant Ingrevia Transcript: Q1 25/26
Specialty and Nutrition segments drove strong Q1 FY26 results, with EBITDA up 29% and PAT up 54% year-on-year. Strategic CapEx, cost optimization, and new export opportunities in Europe position the company for continued growth, with a robust pipeline across key markets.
Jubilant Ingrevia Q1 Results: Revenue flat at Rs 1037 crore, Net Profit surges 54% YoY
Jubilant Ingrevia Limited reported its financial performance for the quarter ended June 30, 2025 (Q1 FY26), showcasing a strong improvement in profitability. Key Highlights: Revenue from Operations: ₹...
Jubilant Ingrevia shares jump nearly 5% after block deal worth Rs 666.88 crore
Shares of Jubilant Ingrevia Ltd surged 4.52% to ₹712.80 on Friday morning following a large block deal involving 98.65 lakh shares. The deal, valued at ₹666.88 crore, saw shares exchanged at ₹676 apie...
Jubilant Ingrevia Block Deal: 98.65 lakh shares worth Rs 666.88 crore change hands
In a significant market transaction on Friday, 98.65 lakh shares of Jubilant Ingrevia Ltd were exchanged via a block deal, amounting to a total value of ₹666.88 crore. The shares were traded at ₹676 a...
Why are Jubilant Ingrevia shares up over 4% today?
Shares of Jubilant Ingrevia rose by 4% following reports of a major explosion at a chemical plant operated by Shandong Youdao Chemical in China’s Shandong province. The blast, which reportedly killed ...
Nuvama maintains ‘Buy’ on Jubilant Ingrevia, trims EPS estimates; target price set at Rs 868
Nuvama has reiterated a ‘Buy’ rating on Jubilant Ingrevia shares, with a target price of ₹868, implying strong upside from the current market price of ₹705.00. The brokerage acknowledged an in-line Q4...
Stocks to watch on brokerages: Tata Steel, Jubilant Ingrevia, UPL, Tata Motors, Bharti Airtel, OMCs, Auto stocks in focus today, on May 14
hares of several frontline and midcap companies are in focus today after global and domestic brokerages released updated ratings and target prices. While Tata Steel and Jubilant Ingrevia received posi...
Jubilant Ingrevia Transcript: Q4 24/25
Q4 saw strong margin and profit growth, with specialty chemicals and nutrition driving performance. Cost optimization and new capacity ramp-up supported a 153% YoY PAT increase, while CapEx and sustainability initiatives position the company for continued growth.
Jubilant Ingrevia Q4 results: Net profit jumps 155% YoY to Rs 74 crore despite 2.2% revenue dip
Jubilant Ingrevia reported a significant jump in its consolidated net profit for the fourth quarter ended March 31, 2025, with profits rising 155% year-on-year to ₹74 crore, up from ₹29 crore in the s...
Jubilant Ingrevia partners with O2 Power to source renewable energy for Bharuch facility
Jubilant Ingrevia Limited has entered into a power purchase agreement with O2 Power to supply renewable energy to its SEZ Bharuch manufacturing facility in Gujarat. The agreement marks a major step to...
Jubilant Ingrevia Transcript: Q3 24/25
Q3 FY25 saw strong year-on-year growth, led by specialty chemicals and nutrition, with EBITDA up 42% and PAT up 80%. Specialty and nutrition now contribute 62% of revenue and 87% of EBITDA, while new vitamin B3 capacity and major CDMO contracts support future growth.
Jubilant Ingrevia Q3 FY25 results: Revenue rises 9.3% YoY to Rs 1,056.77 crore, profit surges 73.6% YoY to Rs 95.57 crore
Jubilant Ingrevia Limited reported its financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2024. The company’s total revenue in Q3 FY25 stood at ₹1,056.77 crore, marki...